)
)
Launching Conversational Triage: Combining LLMs with Bayesian Models
Discover conversational triage, an enhanced healthcare AI product with improved patient understanding, language capabilities, and empathy.
)
Moving towards clinically validated Neuro-Symbolic AI
Infermedica's vision for Gen AI in healthcare. Combining LLMs with clinically validated knowledge to create a conversational, trusted healthcare companion.
)
Infermedica 2024: Year in review
Discover amazing insights into Infermedica’s achievements in 2024, including innovations in product and peer-reviewed research into virtual triage
)
Influencing patient behavior with virtual triage
How can virtual triage affect patient behavior and guide patients to the most appropriate care? Discover compelling stats from peer-reviewed papers
)
Infermedica 2023: Year in review
A reflection of Infermedica's achievements in 2023 and a look ahead to 2024.
)
Infermedica raises $30 M in Series B funding
We’re proud to announce another landmark occasion that enables Infermedica’s growth on a mission for better healthcare.
)
Infermedica 2021: Year in Review
A roundup of what we’ve accomplished in 2021, and what’s to come next year from Infermedica’s CEO, Piotr Orzechowski.
)
Infermedica 2020: Year in review
Infermedica navigated through 2020 and despite all obstacles, we kept supporting global healthcare to bring better health services. See what we achieved.
)
Infermedica closes Series A funding with $10.25M
We are entering the next stage of growth. See how the new funds will accelerate the development of our AI-based solutions for healthcare.
)
COVID-19 Risk Assessment tool is here
As the pandemic emerged, our team worked non-stop and released a free COVID-19 risk evaluation tool.
)
COVID-19 and Infermedica
COVID-19 is more than just a hot topic. Helping patients quickly assess their risk of coronavirus is how we are fighting this global crisis.
)
Infermedica 2019: Year in Review
2019 was a breakthrough. We've managed to grow our team, gain new clients, improve the product, and raise additional funding.
)